Gene clues may explain why light therapy helps some transplant patients
NCT ID NCT07316829
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at gene activity in blood cells from 30 kidney or lung transplant patients who have chronic rejection. Researchers want to find out why some patients improve with a treatment called extracorporeal photoapheresis (ECP) while others do not. The goal is to better understand the body's response, not to test a new cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTIBODIES, DONOR-SPECIFIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, 27100, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Which diuretic protects a new kidney best? a Head-to-Head trial puts furosemide and mannitol to the test
- Blood markers may flag lung transplant danger — study investigates
- Your genes may hold the key to safer lung transplants
- Can a tailored self-management program improve health outcomes for those with serious mental illness?
- Blood test clues could make antifungal dosing safer for transplant patients
- New Two-Step therapy aims to stop chronic kidney transplant rejection